{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:59:47Z","timestamp":1764997187052,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Oncosec"},{"name":"Philogen"},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Provectus"},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech-Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007174","name":"Array","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001645","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"Glaxo Smith Kline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011338","name":"Astra Zeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Asofarma"},{"DOI":"10.13039\/100005205","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010137","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013278","name":"MEDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LEO"},{"DOI":"10.13039\/100006484","name":"ABBVIE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006484","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"MERCK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000042","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LEO"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Philogen"},{"DOI":"10.13039\/100009689","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009689","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.09.013","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T21:00:35Z","timestamp":1540933235000},"page":"201-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries"],"prefix":"10.1016","volume":"104","author":[{"given":"L.","family":"Kandolf Sekulovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Agarwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cinat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wainstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Caglevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lorigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Duncombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-M.","family":"Forsea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"De La Cruz Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kukushkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gorry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Herceg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Neyns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Arenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bylaite-Bucinskiene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Babovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Banjin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Putnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kirov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ocvirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zhukavets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ymeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Stojkovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.09.013_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2018.09.013_bib2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","article-title":"Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials","volume":"4","author":"Eigentler","year":"2003","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.013_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.013_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","article-title":"Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study","volume":"36","author":"Callahan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib5","series-title":"AACR 2016 annual meeting new orleans","article-title":"Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial","author":"Hodi","year":"2016"},{"key":"10.1016\/j.ejca.2018.09.013_bib6","first-page":"36","article-title":"4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006","author":"Long","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib7","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Dummer","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","article-title":"European dermatology forum (EDF); European Association of dermato-oncology (EADO): European organisation for research and treatment of cancer (EORTC). Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016","volume":"63","author":"Garbe","year":"2016","journal-title":"Eur J Cancer"},{"year":"2018","series-title":"NCCN guidelines: melanoma. NCCN version v2","key":"10.1016\/j.ejca.2018.09.013_bib9"},{"key":"10.1016\/j.ejca.2018.09.013_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejca.2017.01.012","article-title":"More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments","volume":"75","author":"Kandolf Sekulovic","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.09.013_bib11","first-page":"999","article-title":"Inequalities in cancer incidence and mortality across medium to highly developed countries in the twenty-first century","volume":"27","author":"Arnold","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejca.2018.09.013_bib12","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jtho.2016.05.030","article-title":"Impact of race on treatment and survival among U.S. Veterans with early-stage lung cancer","volume":"11","author":"Williams","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib13","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaad.2016.06.006","article-title":"Racial disparities in melanoma survival","volume":"75","author":"Dawes","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2018.09.013_bib14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2015.11.019","article-title":"Disparities in melanoma incidence and mortality in South-Eastern Europe: increasing incidence and divergent mortality patterns. Is progress around the corner?","volume":"55","author":"Barbaric","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.09.013_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","article-title":"ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe","volume":"27","author":"Cherny","year":"2016","journal-title":"Ann Oncol"},{"year":"2016","series-title":"Regulatory and reimbursement Alas: a systematic comparison of healthcare systems of 33 European jurisdictions process maps","author":"Wang","key":"10.1016\/j.ejca.2018.09.013_bib16"},{"key":"10.1016\/j.ejca.2018.09.013_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3109\/0284186X.2016.1144934","article-title":"Cutaneous malignant melanoma show geographic and socioeconomic disparities in stage at diagnosis and excess mortality","volume":"55","author":"Str\u00f6mberg","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjd.12923","article-title":"Melanoma prognosis in Europe: far from equal","volume":"171","author":"Forsea","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2018.09.013_bib19","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/annonc\/mdt352","article-title":"Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states","volume":"24","author":"Ades","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaad.2015.09.054","article-title":"Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States","volume":"74","author":"Amini","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2018.09.013_bib21","doi-asserted-by":"crossref","unstructured":"Chino F, Peppercorn JM, Rushin K, Kamal A, Altomare I, Samsa G, Zafar YZ. Out-of-Pocket costs, financial distress, and underinsurance in cancer care JAMA Oncol. doi:10.1001\/jamaoncol.2017.2148.","DOI":"10.1001\/jamaoncol.2017.2148"},{"year":"2017","series-title":"The costs of cancer American cancer society cancer action network report","author":"Singleterry","key":"10.1016\/j.ejca.2018.09.013_bib22"},{"key":"10.1016\/j.ejca.2018.09.013_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the costeffectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"24","key":"10.1016\/j.ejca.2018.09.013_bib24","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American society of clinical oncology value Framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2018.09.013_bib25","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib26","unstructured":"reportUNDP Human development report. Available at: http:\/\/hdr.undp.org\/en\/2015-report."},{"key":"10.1016\/j.ejca.2018.09.013_bib27","unstructured":"World Bank Group. Available at: http:\/\/www.worldbank.org\/."},{"key":"10.1016\/j.ejca.2018.09.013_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/eurpub\/cks192","article-title":"A comparative analysis of health policy performance in 43 European countries","volume":"23","author":"Mackenbach","year":"2013","journal-title":"Eur J Publ Health"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.013_bib29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CJI.0000000000000204","article-title":"Pembrolizumab utilization and outcomes for advanced melanoma in US community oncology practices","volume":"41","author":"Cowey","year":"2018","journal-title":"J Immunother"},{"issue":"52","key":"10.1016\/j.ejca.2018.09.013_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009523","article-title":"Dabrafenib plus trametinib for compassionate use in metastatic melanoma: a STROBE-compliant retrospective observational postauthorization study","volume":"96","author":"Mart\u00edn Algarra","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.ejca.2018.09.013_bib31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicenter randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2018.09.013_bib32","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.09.013_bib33","unstructured":"WHO Europe: European observatory on health systems and policies. Available at: http:\/\/www.euro.who.int\/en\/about-us\/partners\/observatory."},{"year":"2011","series-title":"EFPIA market access delay working group","author":"EFPIA W.A.I.T indicator","key":"10.1016\/j.ejca.2018.09.013_bib34"},{"issue":"1","key":"10.1016\/j.ejca.2018.09.013_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12913-017-2304-2","article-title":"Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status","volume":"17","author":"Maniadakis","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"10.1016\/j.ejca.2018.09.013_bib36","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2016.72.2124","article-title":"Trajectories of injectable cancer drug costs after launch in the United States","volume":"36","author":"Gordon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2018.09.013_bib37","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ejca.2018.09.013_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fphar.2017.00171","article-title":"Managed entry agreements for oncology drugs: lessons from the European experience to inform the future","volume":"8","author":"Pauwels","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2018.09.013_bib39","unstructured":"Aitken M. reportMedicine use and spending in the U.S. A review of 2017 and outlook to 2022, IQVIA report. Available at: https:\/\/www.iqvia.com\/institute\/reports\/medicine-use-and-spending-in-the-us-review-of-2017-outlook-to-2022."},{"issue":"5","key":"10.1016\/j.ejca.2018.09.013_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/annonc\/mdx053","article-title":"Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015","volume":"28","author":"Vivot","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.013_bib41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.17925\/EOH.2017.13.02.108","article-title":"What happens when the cost of cancer care becomes unsustainable?","volume":"13","author":"Simoens","year":"2017","journal-title":"Eur Oncol Haematol"},{"key":"10.1016\/j.ejca.2018.09.013_bib42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000446537","article-title":"Early patient access to medicines: health technology assessment bodies need to catch up with new marketing authorization methods","volume":"19","author":"Leyens","year":"2016","journal-title":"Public Health Genom"},{"issue":"Suppl1","key":"10.1016\/j.ejca.2018.09.013_bib43","doi-asserted-by":"crossref","first-page":"i15","DOI":"10.1136\/qshc.2008.028837","article-title":"Quality requirements for cross-border care in Europe: a qualitative study of patients', professionals' and healthcare financiers' views","volume":"18","author":"Groene","year":"2009","journal-title":"Qual Saf Health Care"},{"key":"10.1016\/j.ejca.2018.09.013_bib44","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1200\/EDBK_156142","article-title":"Strategies for sustainable cancer care","volume":"35","author":"Kerr","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2018.09.013_bib45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.critrevonc.2017.12.020","article-title":"ECCO essential requirements for quality cancer care: Melanoma","volume":"122","author":"Wouters","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2018.09.013_bib46","unstructured":"Bray F, Colombet M, Mery L, et\u00a0al, editors Cancer Incidence in Five Continents, Vol. vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: http:\/\/ci5.iarc.fr, accessed [01 Jul 2018]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:23:16Z","timestamp":1760732596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":46,"alternative-id":["S0959804918313832"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}